Forge Therapeutics, Inc.

Forge Therapeutics, Inc. is a biotechnology firm specializing in the development of metalloenzyme-targeted medicines, focused on creating innovative therapeutic solutions for complex diseases. Forge Therapeutics, Inc. is dedicated to developing cutting-edge therapies that target metalloenzymes, which are crucial for various biological functions.

The company is headquartered in San Diego, US. Founded by Zachary Zimmerman, who has a background in creating impactful healthcare solutions, Forge Therapeutics has successfully raised USD 15. 00 mn in Series A funding in April 2017, led by MagnaSci Ventures, with participation from multiple investors, including Alexandria Venture Investments and Evotec SE. The company has engaged in three funding deals to date.

Forge Therapeutics, Inc. focuses on developing a proprietary platform for metalloenzyme-targeted medicines that aims to meet unmet medical needs through innovative solutions. Their primary offerings include targeted therapies that interact specifically with human metalloenzymes, designed to treat complex diseases where traditional therapies have limited effectiveness. The company collaborates with pharmaceutical companies and research institutions primarily in North America and Europe, providing specialized therapies for drug development and research applications.

Forge Therapeutics, Inc. generates revenue through strategic partnerships and collaborations with pharmaceutical and biotechnology companies. Their revenue streams include licensing agreements and research partnerships, allowing clients access to their proprietary drug discovery platform. These business transactions typically involve upfront fees, milestone payments, and royalties from future product sales.

They also offer tailored services to partners, including consultation support for developing metalloenzyme-targeted therapies, though specific pricing details and revenue figures remain undisclosed. Forge Therapeutics, Inc. plans to utilize the USD 15. 00 mn raised in their most recent funding round to advance their development of new metalloenzyme-targeted therapies.

The company is focused on expanding its market reach into new geographic areas across Europe and Asia by 2025. Their strategy includes launching additional products that leverage their innovative platform, aimed at addressing more complex medical needs, while enhancing collaboration with industry stakeholders to strengthen their position in the biopharmaceutical sector.